For expression and delivery of recombinant subunit vaccine antigens including Norwalk virus capsid protein (NVCP), transgenic plants have been created [9]. Clinical trials using potatoes expressing NVCP showed very promising results, with 19 of 20 volunteers showing immune responses against NVCP delivered by ingestion of raw transgenic potatoes containing approximately 500 μg antigen per dose [10]. Previous studies with NVCP expression in tobacco and potato cells demonstrated that subunits assembled to form VLP very similar to those obtained with baculovirus-infected insect cell expression, although up to 75% of the antigen was present as monomers or partially assembled aggregates [9]. VLP assembly may be important for obtaining stability against acid and protease-mediated degradation in the stomach, as well as for presentation of conformation-dependent epitopes that may be needed for effective virus neutralization.

In this study, we expanded our effort to create transgenic plants that express HEV capsid proteins (HEV CP).

2. Materials and methods

2.1. Preparation and purification of rHEV VLP

The molecular cloning and construction of a recombinant baculovirus Ac5480/7126 harboring the HEV capsid protein gene lacking 111 amino acids at the N-terminal were described previously [6]. The rHEV VLP were prepared using Tn5 cells infected with Ac5480/7126 at a multiplicity of infection of 10. Following 7 days of incubation at 26.5 °C, intact cells and cell debris were removed from the culture medium, and the rHEV VLP were concentrated by centrifugation and purified by isopycnic binding in CsCl gradient. A visible band containing rHEV VLP was col-

lected, and the rHEV VLP were diluted and pelleted by centrifugation.

2.2. Western blot assay

Leaf samples were extracted by FastPrep (speed 5, 30 s) in 4 ml/g leaf of 50 mM sodium phosphate pH 6.6, 50 mM NaCl, 50 mM sodium ascorbate, 1 mM EDTA, 1 mM PMSF, 0.1% Triton X-100, and clarified for 2 min at 4 °C in microcentrifuge. Aliquots were subjected to SDS-PAGE, blotted to PVDF membrane, and probed with guinea pig anti-HEV (1:1000), visualized with ECL+ (anti-guinea pig IgG-HRP 1:5000) on STORM scanner.

2.3. Antigen-capture ELISA

Potato leaf or tuber extracts were prepared as described above in Section 2.2. Microtiter plates were coated with 50 μl per well of rabbit anti-HEV serum diluted 1:10,000 in carbonate/bicarbonate coating buffer overnight at 4 °C. Insect cell-derived HEV VLP reference standard was diluted in PBST/1% dry milk at 100 ng/ml and two-fold dilutions down to 3.125 ng/ml. Leaf or tuber extracts were diluted 25- and 50-fold in PBST/1% dry milk. The reference standards and plant extracts were loaded at 50 μl per well and incubated at 37 °C for 1 h. Wells were washed with PBST and then probed with guinea pig anti-HEV serum diluted 1:5000, followed by goat anti-guinea pig IgG-HRP conjugate (Sigma) diluted 1:5000. Color was developed using TMB substrate solution for 5 min.

2.4. Construction of plant expression vector

Intermediate plant expression cassettes were constructed using a vector pIBT210 [11]. Since two truncated forms


Fig. 1. Plant transformation vectors for expression of HEV CP. Binary T-DNA plasmid vectors, pHEV101 and pHEV110, for expression of HEV CP, p54 and p58, are shown. They contain left border (LB) and right border (RB) sequence motifs that delineate the DNA to be transferred (T-DNA) and integrated into nuclear chromosomal DNA. Within the T-DNA borders lies a selectable marker (nlp2), which confers resistance to the antibiotic kanamycin, and will allow specific regeneration of transformed plants. Also included are expression cassettes for HEV CP, which are driven by the constitutive CaMV 35S promoter linked to the tobacco etch virus (TEV) 5′-UTR, which acts as a translational enhancer, and terminated by the soybean VSP 3′ end [9].

of HEV ORF2 appeared to yield VLP assembly in insect cells (ΔN111 and ΔN111/ΔC52), we inserted these into pIBT210. Then, the expression cassettes were transferred into a binary vector (pGPTV-Kan) for use in *Agrobacterium*-mediated delivery of foreign DNA into plant cells. These constructs, pHEV101 (ΔN111/ΔC52) and pHEV110 (ΔN111), are shown in Fig. 1.

3. Results

3.1. Characterization of rHEV

The capsid proteins of HEV with its N-terminal 111 amino acids truncated were expressed with a recombinant baculovirus in insect cells, where the capsid proteins self-assembled into VLP [6]. The rHEV VLP were purified by centrifugation and characterized by SDS-PAGE and Western blot assay, where a major protein band with a molecular weight of 54 kDa was observed. The particles possess antigenicity similar to that of authentic HEV particles and consequently they appear to be a good antigen for the sensitive detection of HEV-specific IgG and IgM antibodies [12]. Furthermore, the VLP may be the most promising candidate for an HEV vaccine owing to its potent immunogenicity [7,8]. Therefore, we used the same construct to express HEV CP in the transgenic plant.

3.2. Coding sequence analysis

We first examined the coding sequence for the HEV CP to determine whether the nucleotide sequence should be altered for optimization of plant expression. Codon use is fairly favorable to both dicot and monocot plants. Of 660 total codons, 3.6% are monocot-unfavorable and 12.8% are dicot-unfavorable, defined as either making up less than 10% of codon choice for that amino acid or less than one third the frequency of the most popular codon for that amino acid, inclusive.

3.3. Expression in potato plants

We used pHEV101 and pHEV110 for transformation of potato "Desiree" as described [9,13]. After regeneration of multiple independent kanamycin-resistant lines, we screened leaf samples by ELISA for HEV CP expression. Expression levels ranged up to approximately 0.33% total soluble protein, which is similar to the levels we obtained for NVCP [9]. There was no apparent difference in expression from either construct pHEV101 (ΔN111/ΔC52 coding sequence) and pHEV110 (ΔN111 coding sequence) as the range and maximal expression were similar for both.

We selected the best lines for transplant to the greenhouse and after 2 months growth we assayed leaves for expression of HEV CP by ELISA. We observed that the antigen


Fig. 2. Expression of HEV CP in tubers of transgenic potato lines. HEV101 (10 lines) or HEV110 (6 lines) tubers were extracted and assayed by ELISA for HEV CP. Error bars indicate standard error for three different tubers from the same line.

Fig. 3. Western blot of HEV CP expressed in potato leaves. Leaf samples were extracted by FastPrep and clarified by centrifugation. Aliquots were subjected to SDS-PAGE, blotted to PVDF membrane, and probed with guinea pig anti-HEV, visualized with ECL+ on STORM scanner. Lanes are: (1) 50 ng HEV VLP from baculovirus-infected insect cells, (2) 25 ng HEV VLP, (3) 12.5 ng HEV VLP, (4) untransformed Desirée extract, (5) BioRad Kaleidoscope Molecular Weight Marker, (6) HEV101(EHA)/5, (7) HEV101(EHA)/12, (8) HEV101(EHA)/16, (9) HEV101(EHA)/17, (10) HEV101(LBA)/11, (11) HEV101(LBA)/14, (12) HEV110/1, (13) HEV110/2, (14) HEV110/11 and (15) HEV110/12. Bold arrow indicates major band of VLP sample that corresponds to the 54 kDa HEV CP; thin arrows indicate products of proteolysis.

expression on a total protein basis was reduced four- to five-fold compared to that in tissue-cultured plantlets. This is not unexpected, since soil-grown plants in natural light have higher levels of total leaf protein. Further, it is possible that the recombinant antigen is less stable in the soil-grown plants.

3.4. HEV CP expression in potato tubers

Ten independent transgenic lines of HEV101 and six lines of HEV110 were grown to maturity in the greenhouse and tubers were harvested and washed. ELISA for HEV CP was performed on tuber extracts as described for leaf extracts. Accumulation of HEV CP in tubers varied from about 5 to 30 μg/g fresh tuber, depending on the transgenic plant line (Fig. 2). This compares well with the expression of NVCP in potato tubers [9] and is better than expression of E. coli LT-B protein in potato [13]. We further compared the expression levels with the yield of tubers for each line. Tuber yield varied less than expression levels, and ranged from about 600 to 1000 g per pot. We used these data to select lines HEV101-16, HEV101-23, HEV110-27, and HEV110-28 for highest yields of recombinant protein.

Western blot of transgenic potato leaf extract showed that most of the recombinant HEV CP accumulated as 54 kDa, similar to the insect cell-derived antigen (Fig. 3). Some apparent proteolytic products of lower M_r were observed in both insect cell- and potato-derived material. HEV CP in plants transformed with either HEV101 or HEV110 showed similar patterns, with no qualitative or quantitative differences apparent. Failure to detect a larger protein for the single-truncation HEV101 (ΔN111) than that observed for the double truncation HEV110 (ΔN111/ΔC52) suggests that the ΔC52 truncation may occur in planta via an endogenous protease.

4. Discussion

HEV CP has been expressed in baculovirus-infected insect cell system and shown to assemble VLP [6,14]. The VLP have several advantages for the mucosal immunogen as follows: (1) rHEV VLP are composed of a single protein assembled into particles without nucleic acid. (2) rHEV VLP are easy to prepare and purify in a large quantities, approximately 1 mg per 2 × 10^7 insect cells. (3) rHEV VLP are antigenically similar to the native virion. (4) rHEV VLP are highly immunogenic in experimental animals when injected parenterally.

Our goal is to create transgenic plants that express HEV CP in edible tissues as VLP, in order to obtain an economical oral vaccine. It is likely that the success of oral delivery using VLP from insect cells is due to the particulate structure of the antigen, which contributed either to enhanced resistance to degradation in the gut or to enhanced uptake into the gut immune system.

In our studies with potato expressing HEV CP, we found very few VLPs, with the great majority of ELISA-positive antigen remaining near the top of a sucrose gradient (data not shown). Oral immunization of mice with potatoes expressing HEV CP failed to elicit detectable antibody responses in serum (data not shown). We extracted fecal pellets on day 18 after oral immunization on day 17 to evaluate the content of ELISA-reactive HEV capsid protein. Substantial antigen (3–4% of the dose) was present in pellets of mice that were fed HEV CP potato or gavaged with insect cell-derived VLP. Thus, the potato cells probably provided some protection to the soluble HEV CP present in potato tubers, and perhaps even limited uptake of antigen that may have been present as VLP. Since orally delivered insect cell-derived VLPs stimulated antibody responses and protected monkeys against HEV challenge [8], it is likely that poor VLP assembly in potato

was a major factor in the lack of oral immunogenicity of potato-derived HEV CP in mice. Future studies should focus on the optimization of VLP assembly in plant tissues, which may involve alternative plant host systems, and/or tissue and subcellular targeting of antigen.

Acknowledgements

References

[1] Purcell RH, Emerson SU. Hepatitis E virus. In: Knipe DM, Howley PM, editors. Fields Virology, vol. 1. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 3051–61.

[2] Khuroo MS. Study of an epidemic of non-A, non-B hepatitis. Possibility of another human hepatitis virus distinct from post-transfusion non-A, non-B type. Am J Med 1980;68(6):818–24.

[3] Wong DC, Purcell RH, Sreenivasan MA, Prasad SR, Pavri KM. Epidemic and endemic hepatitis in India: evidence for a non-A, non-B hepatitis virus aetiology. Lancet 1980;2(8200):876–9.

[4] Reyes GR, Purdy MA, Kim JP, et al. Isolation of a cDNA from the virus responsible for enterically transmitted non-A, non-B hepatitis. Science 1990;247(4948):1335–9.

[5] Tam AW, Smith MM, Guerra ME, et al. Hepatitis E virus (HEV): molecular cloning and sequencing of the full-length viral genome. Virology 1991;185(1):120–31.

[6] Li TC, Yamakawa Y, Suzuki K, et al. Expression and self-assembly of empty virus-like particles of hepatitis E virus. J Virol 1997;71(10):7207–13.

[7] Li T, Takeda N, Miyamura T. Oral administration of hepatitis E virus-like particles induces a systemic and mucosal immune response in mice. Vaccine 2001;19(25-26):3476–84.

[8] Li TC, Suzaki Y, Ami Y, Dhole TN, Miyamura T, Takeda N. Protection of cynomolgus monkeys against HEV infection by oral administration of recombinant hepatitis E virus-like particles. Vaccine 2004;22:370–7.

[9] Mason HS, Ball JM, Shi JJ, Jiang X, Estes MK, Arntzen CJ. Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice. Proc Natl Acad Sci USA 1996;93(11):5335–40.

[10] Tacket CO, Mason HS, Losonsky G, Estes MK, Levine MM, Arntzen CJ. Human immune responses to a novel Norwalk virus vaccine delivered in transgenic potatoes. J Infect Dis 2000;182(1):302–5.

[11] Haq TA, Mason HS, Clements JD, Arntzen CJ. Oral immunization with a recombinant bacterial antigen produced in transgenic plants. Science 1995;268(5211):714–6.

[12] Li TC, Zhang J, Shinzawa H, et al. Empty virus-like particle-based enzyme-linked immunosorbent assay for antibodies to hepatitis E virus. J Med Virol 2000;62(3):327–33.

[13] Mason HS, Haq TA, Clements JD, Arntzen CJ. Edible vaccine protects mice against Escherichia coli heat-labile enterotoxin (LT): potatoes expressing a synthetic LT-B gene. Vaccine 1998;16(13):1336–43.

[14] Xing L, Kato K, Li T, et al. Recombinant hepatitis E capsid protein self-assembles into a dual-domain $T=1$ particle presenting native virus epitopes. Virology 1999;265(1):35–45.

RESEARCH ARTICLE

DNA vaccine-encapsulated virus-like particles derived from an orally transmissible virus stimulate mucosal and systemic immune responses by oral administration

S Takamura[1], M Niikura[2], T-C Li[3], N Takeda[3], S Kusagawa[4], Y Takebe[4], T Miyamura[3] and Y Yasutomi[1]

[1]Department of Bioregulation, Mie University School of Medicine, Mie, Japan; [2]Department of Virology I, National Institute of Infectious Diseases, Tokyo, Japan; [3]Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan; and [4]Laboratory of Molecular Virology and Epidemiology, AIDS Research Center, National Institute of Infectious Disease, Tokyo, Japan

Delivery of foreign genes to the digestive tract mucosa by oral administration of nonreplicating gene transfer vectors would be a very useful method for vaccination and gene therapy. However, there have been few reports on suitable vectors. In the present study, we found that plasmid DNA can be packaged in vitro into a virus-like particle (VLP) composed of open reading frame 2 of hepatitis E virus, which is an orally transmissible virus, and that these VLPs can deliver this foreign DNA to the intestinal mucosa in vivo. The delivery of plasmid DNA to the mucosa of the small intestine was confirmed by the results of immunohistochemical analyses using an expression plasmid encoding human immunodefi-ciency virus env (HIV env) gp120. After oral administration of VLPs loaded with HIV env cDNA, significant levels of specific IgG and IgA to HIV env in fecal extracts and sera were found. Moreover, mice used in this study exhibited cytotoxic T-lymphocyte responses specific to HIV env in the spleen, Payer's patches and mesenteric lymph nodes. These findings suggest that VLPs derived from orally transmissible viruses can be used as vectors for delivery of genes to mucosal tissue by oral administration for the purpose of DNA vaccination and gene therapy.
Gene Therapy advance online publication, 19 February 2004; doi:10.1038/sj.gt.3302193

Introduction

The successful outcome of novel gene therapies and DNA vaccinations largely depends on the development of effective delivery systems.[1] In human applications, both the efficacy and safety of any delivery system used for gene transfer are major concerns. It has been shown that tissue-specific gene transfer by a viral vector could be achieved naturally and effectively through cell specificity of the virus receptors.[2] However, there is a risk of vector toxicity through viral infection of the host cells. Also, the limited sizes of transgenes often present a serious obstacle. Nonviral vectors, such as liposomes, are safer but do not have a cell-specific targeting component and have limited transduction both in vitro and in vivo. This limitation has been partly overcome by the development of molecular conjugates consisting of cell-specific ligands that confer cell specificity to nonviral vectors.[3,4]

The development of a system for delivering genes to or conferring immunity to mucosal tissue by oral administration would provide a convenient means for effective treatment or prevention of various human

diseases, including cancers, infectious diseases and immunological disorders.[5] Since many pathogenic viruses and bacteria establish their initial infections through the mucosal surface, vaccine strategies that can stimulate mucosal immunity have been widely studied (reviewed in Ogra et al[6]). However, there are several difficulties in oral immunization with nonreplicating molecules, such as low pH in the stomach, the presence of proteolytic enzymes in the digestive tract and the presence of physical as well as biochemical barriers associated with the mucosal surface itself.[6]

Among the various nonreplicating molecules, a virus-like particle (VLP), an empty particle with a structure similar to that of an authentic virus particle, offers the possibility of a new approach for vaccine development.[7] It is expected that the VLP structure will provide resistance to severe environments in the digestive tracts and enable specific binding to the mucosal surface if an appropriate VLP is chosen.[8] However, VLPs can induce immune responses to themselves, and this is a problem for using VLPs as a vaccine vector to carry foreign DNA. A system using polyoma virus VP1 VLPs as a carrier of DNA by intranasal administration has been reported.[9] These VLPs work as an adjuvant, since DNA vaccine can induce immune responses by intranasal administration without VLPs. Hepatitis E virus (HEV) is an unclassified calicivirus-like, positive-strand RNA virus that causes

Figure 1 Electron micrographs of HEV-VLPs: (a) purified HEV-VLPs before treatment; (b) disassembled HEV-VLPs after treatment of VLPs with EGTA and DTT; and (c) refolded HEV-VLPs in the presence of CaCl₂, DMSO and DNA. Bars represent 50 nm.

human acute hepatitis by fecal–oral transmission. HEV first infects epithelial cells of the small intestine and then reaches the liver through the portal vein. It has recently been reported that overexpression of a part of open reading frame 2 (ORF2) in a baculovirus expression system results in the assembly of this protein into a VLP.[10] We have also reported that VLPs carrying foreign epitopes elicit strong mucosal and systemic immune responses to both the VLPs and exogenous epitopes without the requirement of any kind of adjuvant when orally administered to mice.[11]

Since infection with human immunodeficiency virus (HIV) most likely occurs through exposure of mucosal tissue to the virus, HIV-specific immune responses at mucosal sites are critical for the initial control of infection. Therefore, a nonreplicating vaccine vector that elicits mucosal immunity by oral administration would be a powerful HIV vaccine. In the present study, we found that unrelated plasmid constructs can be encapsulated into HEV-VLPs and delivered to the intestinal mucosa by oral administration. HIV DNA vaccine-loaded HEV-VLPs can elicit mucosal and systemic cellular as well as humoral immune responses by oral administration.

Results

In vitro refolding of VLPs

The HEV-VLPs produced by a recombinant baculovirus system were disassembled by the removal of calcium ions (Figure 1b). When calcium ions were supplemented to the disrupted VLPs in the presence of plasmid DNA, the DNA was encapsulated into the refolded VLPs (Figure 1c). No significant morphological difference due to the VLP disassembling–refolding process was observed under an electron microscope.

Density shifts of VLPs and amount of plasmid DNA after DNA encapsulation

Plasmid DNA encapsulation in the refolded VLPs was confirmed by CsCl equilibrium gradient centrifugation. VLP density is greater when loaded with a DNA plasmid. A heavier density gradient peak was present only when DNA was incorporated into the VLPs (Figure 2d). A single lighter density peak was produced for VLPs alone (Figure 2a), refolded VLPs (Figure 2b) and intact VLPs in the presence of plasmid DNA (Figure 2c). Despite the various sizes of plasmid DNA used for

Figure 2 CsCl gradient profiles of intact and refolded VLPs. No DNA added: (a) intact; (b) refolded. DNA added: (c) intact; (d) refolded. The amount of DNA encapsulated in VLPs is expressed as μg (e) and molality (f) per 50 μg VLP protein.

encapsulation, the amounts of plasmid in VLPs were almost the same (17–19 μg per 50 μg of HEV-VLPs) (Figure 2e and f). A solution with a high concentration of plasmid DNA showed high viscosity, and VLPs including DNA were not obtained for general use in experiments. Based on these results, we used this amount (1 mg/ml) as the optimal concentration (data not shown).

Gene transfer by HEV-VLPs

Initially, four cell lines derived from mice, rabbits, monkeys and humans were studied for their ability to

transfer genes *in vitro*. The fluorescence of GFP-expressing cells was observed under a fluorescence microscope. Although the percentages of fluorescence-positive cells were not so high (11.2% of NIH3T3 cells, 19.6% of RK-13 cells, 21.0% of COS-7 cells and 20.1% of HepG2 cells), all of the cell lines used in this study showed positive reactions (Figure 3). In contrast, no fluorescence-positive cells were observed when the cells were incubated with plasmid DNA alone or intact VLPs in the presence of plasmid DNA (data not shown). We next tried gene transduction *in vivo*. Mice that had orally received a vaccine of DNA expressing HIV env gp120 of the NL432 strain (pJWNL432) that was encapsulated in VLPs were killed 2 days after immunization, and the expression of HIV env protein in the digestive tract was examined. HIV env protein was found in epithelial cells of the small intestine by immunohistochemistry (Figure 4), indicating that the HEV structure necessary for the entry of HEV into target cells had been preserved in refolded VLPs and that the DNA encapsulated in HEV-VLPs had been delivered to intestinal tissues.

Systemic and mucosal HIV-specific humoral immune responses in mice that had orally received a vaccine of HIV DNA encapsulated in VLPs

Mice were orally or subcutaneously immunized four times at 1-week intervals with pJWNL432 either naked or encapsulated in HEV-VLPs. The serum levels of HIV env-specific IgG antibodies in mice that had received loaded VLPs were significantly higher than those in mice that had received naked DNA ($P < 0.05$ at 12 wpi, Figure 5a and e). Moreover, specific IgA was detected at high levels in sera of mice that had received loaded VLPs but not in sera of mice that had been immunized subcutaneously ($P < 0.05$ at 12 wpi, Figure 5b and f). HIV env-specific IgA was only detected in fecal extracts of mice that had orally received pJWNL432-encapsulated HEV-VLPs (Figure 5d and h). No specific IgG was detected in any of the fecal

samples (Figure 5c and g). The levels of HIV env-specific IgG antibodies detected in sera from subcutaneously and orally immunized mice were the same (Figure 5a and e). HEV-specific IgA was detected in both sera and fecal extracts of mice that had been orally administered VLP but not in sera or fecal extracts of mice that had been immunized subcutaneously (Figure 5j and l). Both orally and subcutaneously immunized mice showed HEV-specific IgG in sera (Figure 5i) and fecal extracts (Figure 5k).

Elicitation of HIV-specific cytotoxic T lymphocytes at systemic and mucosal sites by oral administration of a vaccination of HIV DNA encapsulated in VLPs

Cytotoxic T lymphocyte (CTL) responses in the spleen, mesenteric lymph nodes (MLN) and Payer's patches (PP) were investigated at 5 weeks after the first immunization. Mice that had orally received pJWNL432 encapsulated in HEV-VLPs showed HIV env epitope-specific CTL responses in the spleen, MLN and PP, whereas cells from the same tissues in mice that had received naked DNA vaccine did not show any CTL activity (Figure 6a). The P18 peptide is a dominant HIV env CTL and Th cell epitope in BALB/c mice and is restricted to the H-2D^d allele. These effector cell functions derived from our experiments were inhibited by either anti-CD8 or -H-2D^d monoclonal antibody (mAb) (Figure 6b,c), indicating that oral immunization of mice with a vaccine of HIV env DNA-encapsulated HEV-VLPs elicited CD8$^+$ and MHC class I-restricted CTLs both locally and systemically.

Discussion

A large number of pathogens gain access to the human body via mucosa such as oral, nasal or genital mucosa. The best defense against these predominantly mucosal


Figure 3 Expression of GFP in cells transfected with plasmid DNA encapsulated in HEV-VLPs: (a) NIH/3T3 cells (mouse); (b) RK-13 cells (rabbit); (c) COS-7 cells (monkey); and (d) HepG2 cells (human).

Figure 4 Immunostaining of serial sections of small intestine tissue from mice 2 days after oral administration of pJWNL432-encapsulated VLPs. HIV env proteins were observed in epithelial cells (arrow) (b, c), and control mAb did not show any positive reactions (d). Control mice were also administered pJWNL432 without VLP encapsulation (a). Bar marker represents 50 μm.


Figure 5 IgG (a, c, e ,g, i and k) and IgA (b, d, f, h, j and l) levels in sera (a, b, e, f, i and j) and fecal extracts (c, d, g, h, k and l) of immunized mice. Mice were orally (■) or subcutaneously (□) administered pJWNL432 encapsulated in VLP or naked (■). Symbols indicate HIV env-specific antibody levels. Background levels to HIV env in nonimmunized mice (■) are also shown. The IgG and IgA antibody levels are expressed as OD at dilutions of 1:100 and 1:2 for serum and fecal extracts, respectively. The mean OD values ±s.e.s were obtained from five mice/group.

Figure 6 Spleen, MLN and PP cells from mice orally administered pJWNL432-encapsulated VLPs elicited CTL. (a) Mice were orally administered pJWNL432 encapsulated in VLPs (circles) or naked (triangles). Results for nonimmunized controls are also shown (×). (b) Effector cells obtained from the spleen, MLN and PP cells of mice orally administered pJWNL432-encapsulated VLPs are mediated CD8⁺ cells. Lytic activities of effector cells were assessed in the presence of anti CD4 mAb, anti-CD8 mAb or medium. Effector:target ratio was 80:1. (c) HIV env-specific lysis was restricted by MHC class I. Effector cells were examined for P18-specific lytic activities in the presence of anti-H-2K^d, anti-H-2D^d or H-2L^d mAb. The percentage of P18-specific lysis was calculated as (% lysis of target cells labeled with P18)−(% lysis of target cells labeled with control peptide). Each value is the mean percentage of the specific lysis values obtained from five mice.

pathogens is mucosal vaccines that are capable of inducing both systemic and mucosal immunity. Recent evidence has shown that DNA vaccination can confer protection against a number of infectious agents, including viruses and bacteria, although peripheral immunization with naked DNA is less than optimal for stimulating mucosal immunity.[12,13] In fact, it is quite difficult to induce both mucosal and systemic immune responses by oral administration of naked DNA. This study demonstrated that an orally administered DNA vaccine encapsulated in an orally transmissible virus-derived VLP induced both mucosal and systemic immunity.

The delivery of a DNA vaccine for induction of mucosal immune responses is usually achieved by gene transfer to the upper nasopharynx-associated lymphoid tissue (NALT), upper airway, salivary glands and tonsils.[5,14] Despite its obvious convenience, oral administration is rarely successful, since it is quite difficult to protect plasmid DNA from the environment in the

digestive tract. The efficacy of orally delivered DNA vaccine to NALT is improved by encapsulating plasmid DNA in poly (lactide-coglycolide) (PLG) microparticles for protection against the gastric environment.[15,16] The immune responses to particle-borne DNA immunizations by means such as utilization of a gene gun or PLG differ from those to DNA immunizations without particles.[13] It is thought that the microparticles are actively taken up by cells such as macrophages or M cells of PP of the small intestine and thus facilitate the presentation of antigens to local immune systems.[15,17] This mechanism is the same as that of gene gun immunization of a DNA vaccine, that is, phagocytic cells such as macrophages or dendritic cells take up plasmid DNA delivered by a gene gun. The delivered gene is expressed only in these cells.[18] Similarly, only mucosal immunity was induced in mice by oral administration of DNA-encapsulated PLG microparticles.[15,16] It is likely that the mechanism underlying immune recognition of

HEV-VLP infection is similar to that of direct intramuscular or subcutaneous DNA immunization without the use of particles. Protein expressed by HEV-VLP-infected cells is recognized by the immune surveillance system, resulting in the elicitation of Ag-specific immune responses. We showed in this study that genes could be expressed in epithelial cells in the small intestine after delivery by HEV-VLPs (Figure 4). It is plausible that HEV-VLPs, which are derived from an orally transmissible virus, were incorporated into HEV-permissive epithelial cells in the small intestine, because they retained structures and properties similar to those of HEV particles, producing an infection similar to that induced naturally.[19] The Ag-expressing cells might be recognized by intraepithelial lymphocytes or submucous antigen-presenting cells by the same mechanism as that in the case of general virus infection.

An HEV-VLP has several advantages as a vector of DNA. Firstly, in our experience, large amounts can be easily obtained from standard cultivation protocols compared with the amounts of other VLPs obtained. The yield of purified HEV-VLPs collected from a culture supernatant of 50–100 µg/ml is more than 100 times greater than that of other VLPs. Secondly, the outcome of gene delivery in humans can be predicted using conventional laboratory animals, since HEV naturally infects various animals as well as humans through the same infectious route and target cells.[10,20] Thirdly, HEV-VLPs are stable at room temperature. Fourthly, anti-HEV immune responses had no effect on DNA administration in the present study, and this might be related to the neutralizing antibody for preventing infection with HEV. Neutralizing antibodies to HEV for inhibiting infection have not yet been found. This is also the case for HCV. The mechanism by which HEV is eliminated by antibodies is thought to be antibody-dependent cell-mediated cytotoxicity (ADCC). The effect of induction of immune responses to DNA vaccine in our system is not clear. Thus, HEV-VLPs are an attractive vaccine vector in developing countries because these VLP can be preserved without the requirement of any particular equipment. Finally, we have reported that an HEV-VLP can carry foreign amino-acid sequences as a part of the ORF2 protein exposed on the particle surface without any morphological or biological alteration.[10] Liposomal vectors resembling retroviral envelopes endowed with targeting molecules for gene delivery have been reported. The vicronectin receptor, $\alpha_v\beta_3$-integrin, is commonly upregulated on malignant melanoma cells, and liposome carrying an Arg-Gly-Asp (RGD) integrin-binding motif has been used for a system to deliver DNA to these tumor cells.[21] It has also been reported that targeting DNA to M cells by intranasal administration for the induction of mucosal and systemic responses can be achieved by formulating DNA with polylysine linked to viral adhesion.[22] It may be possible to design chimeric ORF2 proteins carrying these targeting molecules to re-target HEV-VLP to particular cell types.

Oral vaccination has obvious advantages for a field trial in a large-scale public health vaccination program.[23] From a practical standpoint, oral administration is less stressful for vaccine recipients and does not require professional skill for the vaccine administration. Moreover, delivery of vaccines via the intestinal tract is considered to be inherently safer than systemic injection.

Encouraging results of phase I trials using Norwalk virus VLPs have recently been reported.[24] Trials using DNA vaccines for infectious and malignancy diseases have also been conducted.[25] The results of the present study suggest that oral administration of DNA vaccine encapsulated in oral transmissible virus VLPs, HEV-VLPs, is effective for inducing both humoral and cellular immunity locally as well as systematically. HEV-VLPs might be useful not only for vaccination but also as a vector in human gene therapy.

Materials and methods

Mice
BALB/c female mice were purchased from Clea Japan (Tokyo, Japan) and were housed in the Laboratory Animal Center of Mie University School of Medicine during the experimental period.

Peptide synthesis
The peptides used in this study were the HIV env CTL epitope (HIV 308-322, RIQRGPGRAFVTIGK; P18)[26] and a control peptide (HCV nonstructural protein 5 CTL epitope MSYSWTGALVTPCAAE; P17).[27]

Plasmid DNA
A highly efficient mammalian expression vector, pJW4303,[28] was used for efficient expression of HIV env gp120 of the NL432 strain.[29] Various sizes of plasmid DNA were also used for the *in vitro* packaging experiment (3.162 kb: pUC118; 5.93 kb: pJW322; 8.63 kb: pJWSIVenv; 11.2 kb: pABWN).

Production and purification of HEV-VLPs
HEV-VLPs were produced and purified by previously described methods.[10,11] Briefly, Tn5 cells maintained in Excel 405 serum-free medium (JRH, KS) were infected with the recombinant baculovirus expressing HEV-ORF2 at an m.o.i. of >5 and cultured for 6 days. The supernatant was harvested and the recombinant baculovirus in the supernatant was pelleted by ultracentrifugation at 10 000 g for 30 min at 4°C. The VLPs in the supernatant were collected by further ultracentrifugation at 100 000 g for 2 h at 4°C. Pelleted VLPs were then resuspended in 10 mM potassium-[2-(N-morpholino) ethanesulfonic acid] (MES) buffer (pH 6.2) and purified on a CsCl equilibrium density gradient. The purified HEV-VLPs were spun down and resuspended in potassium-MES buffer and kept at 4°C.

DNA packaging
Plasmid DNA was encapsulated into HEV-VLPs according to a previously described procedure.[30] Purified VLPs (50 µg) were disrupted by incubation in 180 µl of a buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EGTA and 20 mM dithiothreitol. Following 30 min of incubation at room temperature, 200 µg (20 µl) of each plasmid in 50 mM Tris-HCl buffer (pH 7.5) and 150 mM NaCl was added. The disrupted VLP preparation was refolded by incubation for 1 h with increasing concentrations of $CaCl_2$ up to a final concentration of 5 mM. VLPs were pelleted by ultracentrifugation and resuspended in 10 mM potassium-MES buffer (pH 6.2). At each step, the VLP structure formation was confirmed by electron

microscopy after negative staining, as described previously.[11] To estimate the amounts of encapsulated plasmid DNA, refolded and purified VLPs were treated with 10 IU benzonase (SIGMA-ALDRICH, Irvin, UK) for 1 h at 20°C to remove DNA on the surfaces of VLPs and disrupted with EGTA (1 mM). Absorbance of the supernatant was measured for detection of plasmid DNA contents.

Density analysis of refolded VLPs
Refolded VLPs were separated on a CsCl equilibrium density gradient and fractioned into 0.2 ml aliquots. HEV-VLPs in each fraction were detected by ELISA as previously described,[10] as well as DNA contents.

Gene transfer in mammalian cells
Four cell lines (NIH/3T3 (mouse), RK13 (rabbit), COS-7 (monkey), HepG2 (human)) were used in transfection experiments. Sterilized coverslips were placed in six-well plates, and 5×10^5 cells per well were seeded in the plates. After overnight culture, cells were washed twice with a medium, and about 1 µg of VLP-encapsulated EGFP expression vector (BD Bioscience Clontech, CA, USA) diluted with 0.5 ml medium was added. After 2 h of incubation at 37°C, VLPs were removed. Cells were then incubated for 48 h at 37°C. At the end of the culture period, cells were removed from the culture medium and washed three times with PBS. Coverslips were then mounted onto microscope slide glasses. Fluorescence of the GFP-expressing cells was observed under a fluorescence microscope.

Immunization
Mice were orally immunized four times with 50 µg protein of HEV-VLP/DNA (pJWNL432) complex or 20 µg naked pJWNL432 DNA in 100 µl of potassium-MES buffer at 1 week intervals.

Immunohistochemical analysis
At 2 days after oral immunization, the mice were killed and tissues were collected. Cryostat sections were air-dried and incubated in 0.5% HIO_4 for 10 min to quench endogenous peroxidase activity. The sections were further pretreated with chicken anti-mouse IgG antibody (Chemicon International, Inc., CA, USA) to prevent nonspecific reactions of a secondary antibody. The sections were then incubated with an HIV env-specific mAb (HIV-1 IIIB gp120 mAb (902)), which was obtained through the AIDS Research and Reference Reagent Program,[31] for 30 min at 37°C. The bound antibodies were visualized with a biotinated secondary antibody, HRP-labeled avidin–biotin complex (ABC-peroxidase staining kit, Elite Vector Lab. Inc., CA, USA) and 3.3'-diaminobenzidine tetrachloride with 0.01% H_2O_2. Sections were slightly counterstained with hematoxylin. An mAb (A1/3D1, ANOGEN, Canada) against hepatitis C virus core, which is same isotype to 902, was used as a control.

ELISA
Serum and fecal samples were collected at 0 (preimmunization), 2, 4, 6 and 12 weeks after the first immunization. Feces were suspended in ice-cold PBS at 200 mg/

ml, and the centrifuge supernatant was used as fecal extract. Culture plates (96-well) were coated with purified HEV-VLPs or synthesized oligopeptides (P18) at a concentration of 10 or 100 µg/well, respectively, overnight at 4°C followed by 30 min of blocking with PBS containing 0.1% FBS and 0.05% Tween 20. To determine the anti-HIV env gp120 antibody responses, CV-1 cells were seeded in 96-well plates and infected with recombinant Sendai virus expressing HIV env gp120 of NL432 strain (SeV gp120),[32] and then the plates were incubated at 37°C. At 3 days after infection, plates were washed and fixed with PBS containing 10% formalin for 10 min. Test samples were added to each well and incubated at room temperature for 1 h. For detection of anti-HIV env gp120 antibody, test samples were reacted with wild-type Sendai virus-infected CV-1 cells before addition to the wells to eliminate the nonspecific antibody. Biotin-labeled anti-mouse IgG (Vector, CA, USA) or IgA (CALTAG, CA, USA) was used as the detection antibody. Following 1 h incubation, the plates were washed and further incubated with avidin-HRP (Vector, CA, USA). The reaction was developed using an ABTS substrate (Roch Diagnostic, Mannheim, Germany).

Generation of CTL effector cells
Effector cells were derived from spleen, MLN and PP cells as precursor CTLs. Aliquots of 5×10^6 spleen cells were co-cultured with 2.5×10^6 mitomycin C-treated autologous spleen cells labeled with a peptide at 37°C in a CO_2 incubator. The effector cells generated were harvested after 5 days of culture.

Cytotoxicity assay
Target cells, A20.2J cells (2×10^6), were incubated at 37°C in a 5% CO_2 atmosphere with 10 µg/ml of P18 or control peptide for 16 h. The target cells were then washed and labeled with ^{51}Cr. The ^{51}Cr-labeled target cells were incubated for 5 h with effector cells. Spontaneous release varied from 5 to 10%. Percent lysis was calculated as ((experimental release–spontaneous release)/(100% release–spontaneous release)) × 100. All the experiments were performed at least four times, and each experimental group consisted of five mice.

Blocking of cytolysis
^{51}Cr-labeled target cells (10^6 cells) were preincubated at 4°C for 1 h with anti-H-2 K^d, D^d or L^d mAb (Meiji Institute of Health Science Ltd., Tokyo, Japan) (1 µg/ml), and effector cells were then added. In a separate experiment, effector cells (10^7 cells) were preincubated with anti-CD4 mAb (GK1.5) or anti-CD8 mAb (Lyt2.2) (10 µg/ml) at 4°C for 1 h, and then the labeled target cells were added. Blocking of cytolytic activities by these mAbs was assessed by a 5-h ^{51}Cr release assay.

Statistical analysis
Statistical analysis was performed using Mann–Whitney's U test and Kruskal–Wallis test. Values are expressed as means ± s.d.s. A 95% confidence limit was taken as significant ($P < 0.05$).

8

Acknowledgements

References

1 Hoffmann C et al. Efficient gene transfer into human hepatocytes by baculovirus vectors. Proc Natl Acad Sci USA 1995; 92: 10099–10103.

2 Mistry AR et al. Recombinant HMG1 protein produced in Pichia pastoris: a nonviral gene delivery agent. Biotechniques 1997; 22: 718–729.

3 Schneider H et al. Gene transfer mediated by alpha2-macroglobulin. Nucleic Acids Res 1996; 24: 3873–3874.

4 Afione A, Conrad CK, Flotte TR. Gene therapy vectors as drug delivery systems. Clin Pharmacokinet 1995; 28: 181–189.

5 Morrow CD et al. Recombinant viruses as vectors for mucosal immunity. In: Kraehenbuhl JP, Neutra MR (eds). Defense of Mucosal Surfaces: Pathogenesis, Immunity and Vaccines. Current Topics in Microbiology and Immunology, Vol. 236 Springer-Verlag: Berlin, 1999, pp 255–273.

6 Ogra PL, Faden H, Welliver RC. Vaccination strategies for mucosal immune responses. Clin Microbiol Rev 2001; 14: 430–435.

7 Medina E, Guzman CA. Modulation of immune responses following antigen administration by mucosal route. FEMS Immunol Med Microbiol 2000; 27: 305–311.

8 Ulrich R, Nassal M, Meisel H, Kruger DH. Core particles of hepatitis B virus as carrier for foreign epitopes. Adv Virus Res 1998; 50: 141–182.

9 Clark B et al. Immunity against both polyomavirus VP1 and a transgene product following intranasal delivery of VP1 pseudocapsid–DNA complexes. J Gen Virol 2001; 82: 2791–2797.

10 Li TC et al. Expression and self-assembly of empty virus-like particles of hepatitis E virus. J Virol 1997; 71: 7207–7213.

11 Niikura M et al. Chimeric recombinant hepatitis E virus-like particles as an oral vaccine vehicle presenting foreign epitopes. Virology 2002; 293: 273–280.

12 Etchart N et al. Class-I restricted CTL induction by mucosal immunization with naked DNA encoding measles virus haemagglutinin. J Gen Virol 1997; 78: 1577–1580.

13 Feltquate DM, Heaney S, Webster RG, Robinson HL. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J Immunol 1997; 158: 2278–2284.

14 McCluskie MJ et al. Direct gene transfer to the respiratory tract of mice with pure plasmid and lipid formulated DNA. Antisense Nucleic Acid Drug Dev 1998; 8: 401–414.

15 Kaneko H et al. Oral DNA vaccination promotes mucosal and systemic immune responses to HIV envelope glycoprotein. Virology 2000; 267: 8–16.

16 Chen SC et al. Protective immunity induced by oral immunization with a rotavirus DNA vaccine encapsulated in microparticles. J Virol 1998; 72: 5757–5761.

17 Eldridge JH et al. Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the Payer's patches. J Control Rel 1990; 11: 205–214.

18 Condon C et al. DNA-based immunization by in vivo transfection of dendriric cells. Nat Med 1996; 10: 1122–1128.

19 Li TC et al. Oral administration of hepatitis E virus-like particles induces a systemic and mucosal immune response in mice. Vaccine 2001; 14: 3476–3484.

20 Worm HC, van der Poel WHM, Brandstartter G. Hepatitis E: an overview. Microbes Inf 2002; 4: 657–666.

21 Nahde T et al. Combined transductional and transcriptional targeting of melanoma cerlls by artificial virus-like particles. J Gene Med 2001; 3: 353–361.

22 Wu Y et al. M cell-targeted DNA vaccination. Proc Natl Acad Sci USA 2001; 98: 9318–9323.

23 Nagaraj K, Babu BV. Field trials of oral cholera vaccine in Vietnam. Lancet 1997; 349: 1253–1254.

24 Ball JM et al. Recombinant Norwalk virus-like particles given orally to volunteers: phase I study. Gastroenterology 1999; 117: 40–48.

25 Promoting the free-flow of information within the DNA vaccine community URL: http://dnavaccine.com.

26 Takahashi H et al. An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. Proc Natl Acad Sci USA 1988; 85: 3105–3109.

27 Shirai M et al. Induction of cytotoxic T cells a cross-reactive epitope in the hepatitis C virus nonstructural RNA polymerase-like protein. J Virol 1992; 66: 4908–4106.

28 Yasutomi Y et al. Simian immunodeficiency virus-specific cytotoxic T lymphocyte induction through DNA vaccination of rhesus monkeys. J Virol 1996; 70: 678–681.

29 Adachi A et al. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 1986; 59: 284–291.

30 Touze A, Coursaget P. In vitro gene transfer using human papillomavirus-like particles. Nucleic Acids Res 1998; 26: 1317–1323.

31 Picnus SH, Wehrly K, Chesebro B. Treatment of HIV tissue culture infection with monoclonal antibody–ricin A chain conjugate. J Immunol 1998; 142: 3070–3075.

32 Toriyoshi H et al. Sendai virus-based production of HIV type 1 subtype B and subtype E envelope glycoprotein 120 antigens and their use for highly sensitive detection of subtype-specific serum antibodies. AIDS Res Hum Retroviruses 1999; 15: 1109–1120.

ELSEVIER

Vaccine

Protection of cynomolgus monkeys against HEV infection by oral administration of recombinant hepatitis E virus-like particles

Tian-Cheng Li [a],*, Yuriko Suzaki [b], Yasushi Ami [b], Tapankumar N. Dhole [c], Tatsuo Miyamura [a], Naokazu Takeda [a]

[a] *Department of Virology II, National Institute of Infectious Diseases, Gakuen 4-7-1, Musashi-Murayama, Tokyo 208-0011, Japan*
[b] *Division of Experimental Animals Research, National Institute of Infectious Diseases, Gakuen 4-7-1, Musashi-Murayama, Tokyo 208-0011, Japan*
[c] *Department of Microbiology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow 226014, India*

Abstract

Hepatitis E virus (HEV) is an important causative agent of enterically-transmitted hepatitis. Successful vaccine development is crucial in controlling global HEV infection. HEV capsid protein, with 111 amino acids truncated at the N-terminus, was efficiently expressed in the baculovirus expression system [J. Virol. 71 (1997) 7207–13]. Expressed protein spontaneously assembled into virus-like particles (VLPs) and was released into culture medium. When cynomolgus monkeys were orally inoculated with 10 mg of purified rHEV VLPs, serum IgM, IgG, and IgA responses were observed. All these antibody responses were obtained without adjuvants. When the monkeys were challenged with native HEV by intravenous injection, they were protected against infection or developing hepatitis. These results suggested that recombinant HEV (rHEV) VLPs can be a candidate for the oral hepatitis E vaccine.
© 2003 Elsevier Ltd. All rights reserved.

Keywords: Hepatitis E virus (HEV); Virus-like particles (VLPs); Oral immunization; Vaccine

1. Introduction

Hepatitis E is an acute viral hepatitis caused by infection with hepatitis E virus (HEV) that was first recognized when a large water-borne hepatitis outbreak occurred in India in 1955 [1]. Subsequently, water-borne outbreaks were reported in many developing regions, including Nepal, Burma, China, Middle Asia, the Middle East, Africa, and Mexico, where sanitary conditions are not well maintained [2,3]. HEV is transmitted via an oral-fecal route, often by contaminated drinking water. Hepatitis E affects predominantly young adults [4,5], and the mortality rate is very high, up to 15–20%, in infected pregnant women [6,7]. In developed countries, most cases have been imported. However, recent studies revealed that hepatitis E occurred in patients who had never been abroad [8–10]. Similar viruses to HEV have been isolated from pigs, suggesting that hepatitis E may be a zoonosis [11–13].

HEV has been identified as a 27–34 nm icosahedral particle with an approximately 7.5 kb positive sense RNA genome [14–18]. The HEV genome encodes three open reading frames (ORFs), of which ORF2 is thought to encode the capsid protein. When ORF2, with 111 amino acids truncated at its N-terminus, is expressed in a baculovirus expression system, it spontaneously assembles into virus-like particles (VLPs) [19]. Electron cryomicroscopy shows that these VLPs are formed with 60 copies of a 54 kDa protein arranged in T = 1 symmetry [19–21]. The particles possess antigenicity similar to that of authentic HEV particles and, consequently, they appear to be a good antigen for the sensitive detection of HEV-specific IgG and IgM antibodies. Furthermore, the VLP may be the most promising candidate yet for an HEV vaccine, owing to its potent immunogenicity [19]. Although vaccination is an effective method of infection control for conventional infectious agents, no practical cell culture system to allow the growth of HEV has been established yet, making it difficult to develop a vaccine.

In our previous study, mice orally immunized with purified recombinant HEV (rHEV) VLPs developed serum IgM, IgG, and IgA as well as the fecal IgA antibody responses without an adjuvant [20]. A similar line of the study has been performed with recombinant Norovirus (rNV) VLPs. Oral immunization with rNV VLPs has shown to induce not only systemic but also mucosal immune response in mice, demonstrating that rNV VLPs are an excellent model

---

to study the oral delivery of antigen, and they are a potential mucosal vaccine for NV infection [22]. The safety and immunogenicity of rNV VLPs have been evaluated with healthy volunteers [23].

Because mice are not susceptible to HEV, a protection assay cannot be performed with them. In contrast, macaques (rhesus and cynomolgus monkeys) are sensitive against HEV and are useful models for the study of hepatitis E [24]. When macaques are inoculated with human HEV, they develop acute hepatitis with biochemical, histopathological, and serological markers characteristic of the disease in humans [25,26]. In this study, we demonstrated that oral administration of rHEV VLPs in monkeys-induced serum IgM, IgG, and IgA, anti-HEV antibody responses, and that these monkeys were protected from infection or from developing disease when challenged with native infectious HEV.

2. Materials and methods

2.1. Primates

Cynomolgus monkeys (Macaca fascicularis), born and grown in the Tsukuba Primate Center for Medial Science, National Institute of Infectious Diseases (NIID), were used for the studies. Serum alanine aminotransferase (ALT) values of the animals were normal and stable, and anti-HEV antibody was negative by enzyme-linked immunosorbent assay (ELISA) [29]. Primates were individually housed in BSL-2 facilities. All monkey experiments were reviewed and carried out according to "Guides for animal experiments performed at NIID" under the codes 990058 and 000019.

2.2. Fecal specimen and challenge virus stock

A fecal specimen containing infectious HEV was collected from a patient who developed acute hepatitis in India in 1998. This specimen was suspended in 10 mM phosphate buffered saline (PBS), and a 10% suspension was prepared. The suspension was clarified by centrifugation at 10,000 × g for 20 min, and the supernatant was passed through a 0.45 μm membrane filter (Millipore, Bedford, MA) and stored at −20 °C. This suspension was positive for HEV antigen by an enzyme-linked immunosorbent assay developed in this laboratory and positive also for HEV RNA by reverse-transcription polymerase chain reaction (RT-PCR).

To prepare a challenge virus stock, a 4-year-old male cynomolgus monkey was inoculated intravenously with 2 ml of the filtrate, and stool samples were collected daily after inoculation. Stools collected from 10 to 40 days after injection were positive for HEV antigen by ELISA and HEV-RNA by RT-PCR, respectively. The monkey stool collected at day 21 after inoculation was diluted with PBS to prepare a 10% suspension, and clarified by centrifugation and filtration as described above. The infectivity was determined, and the virus was stored as the challenge virus.

2.3. Infectivity of HEV

Three monkeys were inoculated intravenously with 2 ml of 1:100, 1:1000, and 1:10,000 dilutions of the challenge virus, respectively. Sera were collected weekly before and after the inoculation and used to determine ALT values and to detect HEV antigen. ALT and HEV antigen in serum were monitored to determine the infectivity.

2.4. Preparation and purification of rHEV VLPs

The bile specimens were collected from rhesus monkeys which was injected with a pool of acute-phase stool specimens from patients with sporadic non-A, non-B hepatitis in Myanmar in 1986 [27]. The complete nucleotide (nt) sequence indicated that HEV included in the bile was genotype I HEV [28]. The molecular cloning and construction of a recombinant baculovirus Ac5480/7126 harboring the capsid protein gene lacking 111 amino acids at the N-terminal were described previously [19–21,29]. The rHEV VLPs were prepared using Tn5 cells (High Five™, Invitrogen, San Diego, CA, USA) infected with Ac5480/7126 at a multiplicity of infection of 10. Following 7 days of incubation at 26.5 °C, intact cells and cell debris were removed from the culture medium, and the rHEV VLPs were concentrated by centrifugation for 2 h at 100,000 × g in an SW28 rotor (Beckman Instruments Inc., Fullerton, CA, USA) and purified by isopycnic binding in CsCl gradient. A visible band containing rHEV VLPs was collected, and the rHEV VLPs were diluted five times with phosphate buffered saline solution(−). The rHEV VLPs were pelleted at 100,000 × g and then resuspended in PBS(−). Purity of the rHEV VLPs was evaluated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and electron microscopy after negative staining, as described previously [19].

2.5. Antibody and antigen ELISAs

Serum IgG, IgM, and IgA and fecal IgA antibodies to HEV were detected by antibody ELISAs as previously described [29]. Antigen capture ELISA was used to detect HEV antigen. Briefly, duplicate wells of flat-bottom 96-well polystyrene microplates (Dynex Technologies Inc., Chantilly, VA) were coated with 100 μl of a coating buffer (0.1 M carbonate–bicarbonate buffer, pH 9.6) containing 1:10,000 diluted serum from either non-immunized (normal) rabbit or rHEV VLP-immunized rabbit. The coating was performed at 4 °C overnight. Unbound antibodies were removed, and the wells were washed twice with 10 mM PBS containing 0.05% Tween 20 (PBS-T), and then the blocking was carried out at 37 °C for 1 h with 150 μl of 5% skim milk (Difco Laboratories, Detroit, MI) in PBS-T. When antigen was to be detected in serum, the serum was diluted 1:200 with PBS-T. When the antigen in stool samples was to be detected, the stool was diluted and 10% suspension was prepared with PBS-T containing 1% skim milk. Either 100 μl

of the serum or the same volume of the 10% stool suspension was added to the wells and incubated for 1 h at 37 °C. After the wells were washed five times with PBS-T, 100 μl of hyperimmune serum from guinea pig (1:10,000 dilution with PBS-T containing 1% skim milk) was added to the wells and the plate was incubated for 1 h at 37 °C. The plate was washed five times with PBS-T, and then horseradish peroxidase-conjugated goat anti-guinea pig IgG antibody (1: 2000 in PBS-T containing 1% skim milk) (Cappel, Durham, NC) was added to each well. After incubation for 1 h at 37 °C, the plate was washed five times with PBS-T and 100 μl of substrate o-phenylenediamine and H_2O_2 was added. The plate was left for 30 min at room temperature, and then the reaction was stopped with 50 μl of 4N H_2SO_4. After 10 min, the absorbance at 492 nm was measured with a microplate reader (Molecular Devices Corp., Tokyo, Japan).

2.6. Liver enzyme level

ALT value of infected monkeys was monitored weekly by standard methods (Anilytics, Gaithersburg, MD). The geometric mean of ALT values during the pre-inoculation period of each animal was used as the normal ALT value, and two-fold or greater increase at the peak was considered to be biochemical evidence of hepatitis.

2.7. Detection of HEV RNA by RT-PCR

Total RNA was extracted with RNAzol reagent (Tel-test Inc., Friendswood, TX) using 100 μl of the serum or 10%

fecal suspension. The RNA was purified with Oligotex-dT30 (Roche Diagnostic Systems, Tokyo, Japan) according to the manufacturer's protocol and converted into cDNA as described previously [30]. The cDNA was subjected to polymerase chain reaction with ExTaq DNA polymerase (Takara Shuzo Co. Ltd., Kyoto, Japan) with an external sense primer HEV-D4 (5'-TGTAGAGAATGCTCAGCAGGATAA-3', nt 6391–6414) and an antisense primer HEV-U4 (5'-TAACT-CCCGAGTTTTACCCACCTT-3', nt 7103–7126) using the GeneAmp PCR System 9700 (PE Biosystems, Foster City, CA). Each cycle consisted of denaturation at 95 °C for 30 s, primer annealing at 55 °C for 30 s, and extension reaction at 72 °C for 60 s followed by final extension at 72 °C for 7 min. The nested PCR was done with an internal sense primer HEV-D5 (5'-CTGCCGAGTATGACCAGTCCACTTA-3', nt 6576–6600) and an internal antisense primer HEV-U3 (5'-TTAAGGCGCTGAAGCTCAGCGA-3', nt 7077–7098) under the same conditions, generating a 523 nt fragment.

2.8. Immunization schedule

First, we inoculated two monkeys with each receiving 2 ml of 10% fecal suspension containing infectious HEV at day 96 before the injection (day −96) (M4200 and M4201, Fig. 1). These monkeys recovered from hepatitis E and were used as the serum IgG-positive control. Next, two other monkeys were each orally administered 10 mg of the VLPs on days 0, 7, 21, and 36. The fifth immunization was performed at day 80 (M4364 and M4365, Fig. 1). The third set of two monkeys were orally fed with PBS under the same schedule as the second set of monkeys, and these monkeys were used


Fig. 1. Immunization schedule. Two monkeys (M4200 and M4201) were inoculated with 2 ml of the 10% stool suspension from an acute HEV patient on day −96 and served as serum antibody-positive controls; two monkeys (M4364 and M4365) were inoculated with 10 mg rHEV VLPs on days 0, 7, 21, 36, and 80; two monkeys (M4369 and M4418) received phosphate buffered saline as antibody-negative controls. On day 100, all of these six monkeys were challenged with 2 ml of the challenge virus. Monkey numbers are indicated on the right side of the figure.

as an antibody-negative control (M4369 and M4418, Fig. 1). On day 100, all of these six monkeys were challenged by intravenous injection each receiving 2 ml of challenge virus stock (Fig. 1).

3. Results

3.1. Titration of challenge virus

Three monkeys were inoculated intravenously with 2 ml of 1:100, 1:1000, and 1:10,000 dilutions of the challenge virus, respectively. Sera were collected weekly before and after the inoculation and used to determine ALT values and to detect HEV antigen (Fig. 2). Elevation of ALT was ob-

served in all monkeys, reaching peaks at days 28 and 24 in the monkeys receiving either the 1:100 or 1:1000 dilution and at day 30 in the monkey receiving the 1:10,000 dilution (Fig. 2A). HEV antigen was also detected in the three monkeys, reaching the maximum amount at 2 weeks in the case of 1:100 dilution and at 3 weeks in the cases of 1:1000 and 1:10,000 dilution (Fig. 2B). These results demonstrated that viremia occurred in all monkeys and that all had developed type E hepatitis. Even the 1:10,000 dilution of the suspension was capable of infecting a subject monkey, indicating that the titer of the challenge virus was $>5 \times 10^3$ monkey infectious dose (MID50) per ml of the suspension. These results also indicated that viremia precedes the clinical symptoms associated with ALT elevation, an observation previously described in hepatitis E [31].


Fig. 2. MID50 of the challenge virus. Three serial 10-fold dilutions (1:100 (△); 1:1000 (▽); and 1:10,000 (○)) of the challenge virus were injected intravenously to monkeys. Sera were collected weekly before and after the inoculation. Elevation of alanine aminotransferase (ALT) was determined (A). HEV antigen was detected by the antigen ELISA (B).


Fig. 3. Oral immunization with rHEV VLPs induces serum IgM, IgG, and IgA antibodies in monkeys. Two monkeys (M4364 and M4365) were orally immunized with rHEV VLPs, and serum samples were collected at 1 week intervals. Antibody was detected by the antibody ELISA. OD values of the HEV IgM (□), IgG (○), and IgA (△) antibodies were indicated. The arrows mean the day when the booster injection was performed.

3.2. Kinetics of serum IgM, IgG, IgA, and fecal IgA responses

To evaluate the potential of the rHEV VLPs as an oral immunogen, two cynomolgus monkeys (M4364 and M4365) were immunized orally with 10 mg rHEV VLPs on days 0, 7, 21, and 36. All immunizations were carried out without adjuvant, and the serum antibody responses were monitored by an antibody ELISA (Fig. 3). All of the pre-immune sera taken prior to the first immunization were negative for IgM, IgG, and IgA. The pattern of serum antibody responses was very similar in the two monkeys, although the antibody level was different; M4364 was higher than M4365 in the three antibody levels. A serum IgM response was observed 1 week

post-immunization and reached a maximum at 3–4 weeks. Serum IgG and IgA response was detected at 2 weeks and reached a maximum at 4–5 weeks. These data demonstrated that the rHEV VLPs are immunogenic when delivered orally and that an adjuvant is not required for the induction of serum IgM, IgG, or IgA. Although the antibody titers decreased rapidly after reaching the peak values, IgG and IgA antibody increased very rapidly and reached high titers in 7 days when a boost immunization was performed at day 80 (arrows in Fig. 3). The result indicated that tolerance was not induced. There was no fecal IgA response in either monkey (data not shown). Two monkeys (M4369 and M4418) orally immunized with PBS were negative for IgM, IgG, and IgA throughout the experiment (data not shown).


Fig. 4. Kinetics of biochemical, serological, and virological markers after the challenge. Monkeys recovered from hepatitis E (M4200 and M4201), monkeys orally immunized with HEV VLPs (M4364 and M4365), and monkeys for HEV-antibody negative (M4369 and M4418) were challenged with infectious HEV at day 0. HEV antigen in the serum (△), HEV antigen in the stool (□), IgG antibody in the serum (▽), and ALT elevation (○) were determined. HEV RNA in the sera and stool was monitored by RT-PCR. (+) positive; (−) negative.

3.3. Challenge of monkeys with native HEV

We next addressed whether the monkeys immunized with rHEV VLPs are protected from the challenge by native HEV. Three weeks after the final immunization (day 100), two orally immunized monkeys (M4364 and M4365) were intravenously injected with 2 ml (>1.0 × 10⁴ MID50) of the challenge virus. Two monkeys that had recovered from hepatitis E infection (M4200 and M4201) and two HEV-antibody negative monkeys (M4369 and M4418) were similarly injected and used as controls (Fig. 4).

Both of the HEV-antibody negative monkeys showed a pronounced increase in ALT levels at 5 weeks post-challenge. HEV antigen in serum, a marker of viremia, was observed at 1 week post-challenge. Viral RNA in sera appeared simultaneously and correlated well with the presence of antigen in sera. The viral RNA also appeared in stool specimens at 1 week post-challenge, although the peaks of HEV antigen were slightly delayed when compared with those in matched sera, indicating that efficient HEV infection occurred. IgG antibody in serum was detected at 3 weeks post-challenge and reached a maximum at 6–8 weeks. Fecal IgA was not detected.

In contrast, none of the markers indicating viral infection was observed in the HEV-antibody positive monkeys, M4201 and M4200, demonstrating that these two monkeys were protected from infection even when an amount 100 times greater than MID50 HEV was administered. Fecal IgA was not detected in these monkeys.

Interestingly, neither viremia nor ALT elevation was observed in the orally immunized monkeys, M4364 and M4365. In addition, neither HEV antigen nor HEV-RNA was detected in stool from M4364. Therefore, this monkey was completely protected from HEV infection. However, both HEV antigen and the viral RNA were detected in stool from M4365, although the titer was very low (0.172 OD492) and the RNA was detectable for only 3 days. These results indicated that infection occurred in this monkey, but it did not develop the disease. The increased IgG antibody titer during 2–3 weeks after the challenge was additional evidence of infection. Fecal IgA was not detected in any of the orally immunized monkeys.

4. Discussion

A vaccine against HEV could help to prevent epidemics and sporadic cases of hepatitis E in developing countries and afford protection to travelers to those regions. The feasibility of a hepatitis E vaccine was demonstrated by induction of the serum antibodies to HEV in experimentally infected cynomolgus monkeys [32–34]. Epidemiological studies have also provided evidence that IgG antibody is capable of protecting against HEV infection and demonstrated that HEV IgG persists for a long time after infection [35]. Because no cell culture system that permits the propagation of HEV has been established and the amount of the virus recovered from natural infections in human or experimentally infected primates is relatively small, the use of a recombinant protein may be extremely useful for development of an HEV vaccine. We expressed HEV capsid protein, with 111 amino acids truncated at the N-terminus, using a baculovirus expression system. The truncated 58 kDa protein was further processed to 54 kDa proteins through a post-translational cleavage probably mediated by host cellular protease(s) [19,20]. The rHEV VLPs are easy to prepare and can be purified in large quantities, with a yield of approximately 1 mg per 10⁷ insect cells. The VLPs possess antigenicity similar to that of authentic HEV particles and, consequently, they were good antigen for the sensitive detection of HEV-specific IgG and IgM antibodies. In addition, the VLPs were immunogenic when they were given to mice orally [20].

In this study, we evaluated the ability of rHEV VLPs to induce neutralizing antibodies to HEV when administered orally to cynomolgus monkeys. Our experiments demonstrated that the rHEV VLPs-induced strong immune responses by oral immunization in monkeys. Oral immunization offers many advantages over parenteral immunization, including easy delivery, greater acceptability by recipients, reduction in the required purity, and reduction in the number of trained personnel needed to administer injections, all of which ultimately reduce production costs. We also found that even without adjuvants serum antibody could be induced. The dose of the immunization, 10 mg of rHEV VLPs per 4 kg monkey, was determined based on the immunization of mice, where 50 μg of rHEV VLP was administered to 20 g weight of mice [20]. The suitability of dose and purity of the antigen must be carefully evaluated for future human clinical testing.

Immunological tolerance is of major concern for oral immunization, since the systemic immunological unresponsiveness often occurs after feeding a soluble antigen. Such unresponsiveness also can be induced by feeding the antigen prior to parenteral immunization. However, our experiments demonstrated that oral immunization with the rHEV VLPs did not induce oral tolerance because the antibody titers of IgG and IgA continually increased after each oral immunization, and serum IgA and IgG antibodies increased rapidly and reached high titers after a boost immunization. This is presumably because rHEV VLPs were administered as particles and they were stable at low pH. Perhaps the capsid protein was folded in a structure that avoided oral tolerance. Similar observation has been reported in the experiment using recombinant Norwalk virus VLP [22].

No fecal IgA response was observed in monkeys following oral administration, which is different from the results obtained in mice immunized with rHEV VLPs. The reason is unknown at the moment. Although the cynomolgus monkey is a useful animal for studying HEV infection, many differences are found from the infection in humans. For example, the animals could not be infected with HEV by the oral route [36], and fecal IgA was detected in humans but not in monkeys post-HEV infection (data not shown). It will

be interesting to determine whether the mucosal immune response occurs in humans after oral administration with rHEV VLPs.

We evaluated infection by intravenous challenges with infectious HEV, and acute hepatitis, viremia, and shedding of the virus in feces were detected in all non-immunized animals. By contrast, orally immunized monkeys were protected against HEV infection (M4364) or against developing hepatitis E (M4365), clearly indicating that the serum antibodies induced by oral immunization have the ability to neutralize infectious HEV. In the case of M4365, the antibody titer was much lower than that of M4364 and a small amount virus shedding was observed in the feces a short time after the challenge. This is probably because some viruses escaped neutralization. In this study, the challenge virus was administered intravenously $>10^4$ MID50 of HEV. This titer may be much higher than that found in naturally occurring HEV infections, suggesting that the efficacy of protection depends on the antibody level and challenge virus doses.

In summary, oral immunization with rHEV VLPs without an adjuvant elicited a neutralization antibody that protects monkeys from either infection or developing the disease. The rHEV VLPs can be an oral hepatitis E vaccine.

Acknowledgements

References

[1] Jameel S. Molecular biology and pathogenesis of hepatitis E virus. Expert reviews in molecular medicine 1999, p. 1–16, http://www-ermm.cbcu.cam.ac.uk.

[2] Khuroo MS. Study of an epidemic of non-A, non-B hepatitis. Possibility of another human hepatitis virus distinct from post-transfusion non-A, non-B type. Am J Med 1980;68(6):818–24.

[3] Wong DC, Purcell RH, Sreenivasan MA, Prasad SR, Pavri KM. Epidemic and endemic hepatitis in India: evidence for a non-A, non-B hepatitis virus aetiology. Lancet 1980;2(8200):876–9.

[4] Kane MA, Bradley DW, Shrestha SM, et al. Epidemic non-A, non-B hepatitis in Nepal. Recovery of a possible etiologic agent and transmission studies in marmosets. JAMA 1984;252(22):3140–5.

[5] Myint H, Soe MM, Khin T, Myint TM, Tin KM. A clinical and epidemiological study of an epidemic of non-A, non-B hepatitis in Rangoon. Am J Trop Med Hyg 1985;34:1183–9.

[6] Khuroo MS, Teli MR, Skidmore S, Sofi MA, Khuroo MI. Incidence and severity of viral hepatitis in pregnancy. Am J Med 1981;70(2):252–5.

[7] Balayan MS. Epidemiology of hepatitis E virus infection. J Viral Hepat 1997;4(3):155–65.

[8] Schlauder GG, Dawson GJ, Erker JC, et al. The sequence and phylogenetic analysis of a novel hepatitis E virus isolated from a patient with acute hepatitis reported in the United States. J Gen Virol 1998;79(Pt 3):447–56.

[9] Erker JC, Desai SM, Schlauder GG, Dawson GJ, Mushahwar IK. A hepatitis E virus variant from the United States: molecular characterization and transmission in cynomolgus macaques. J Gen Virol 1999;80(Pt 3):681–90.

[10] Takahashi K, Iwata K, Watanabe N, et al. Full-genome nucleotide sequence of a hepatitis E virus strain that may be indigenous to Japan. Virology 2001;287(1):9–12.

[11] Meng XJ, Purcell RH, Halbur PG, et al. A novel virus in swine is closely related to the human hepatitis E virus. Proc Natl Acad Sci USA 1997;94(18):9860–5.

[12] Okamoto H, Takahashi M, Nishizawa T, Fukai K, Muramatsu U, Yoshikawa A. Analysis of the complete genome of indigenous swine hepatitis E virus isolated in Japan. Biochem Biophys Res Commun 2001;289(5):929–36.

[13] Nishizawa T, Takahashi M, Mizuo H, Miyajima H, Gotanda Y, Okamoto H. Characterization of Japanese swine and human hepatitis E virus isolates of genotype IV with 99% identity over the entire genome. J Gen Virol 2003;84(Pt 5):1245–51.

[14] Purcell RH, Emerson SU, Hepatitis E virus. In: Knipe DM, Howley PM, editors. Fields virology, vol. 1. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 3051–61.

[15] Balayan MS, Andjaparidze AG, Savinskaya SS, et al. Evidence for a virus in non-A, non-B hepatitis transmitted via the fecal-oral route. Intervirology 1983;20(1):23–31.

[16] Reyes GR, Purdy MA, Kim JP. Isolation of a cDNA from the virus responsible for enterically transmitted non-A, non-B hepatitis. Science 1990;247(4948):1335–9.

[17] Tam AW, Smith MM, Guerra ME, et al. Hepatitis E virus (HEV): molecular cloning and sequencing of the full-length viral genome. Virology 1991;185(1):120–31.

[18] Bradley DW, Krawczynski K, Cook Jr EH, et al. Enterically transmitted non-A, non-B hepatitis: serial passage of disease in cynomolgus macaques and tamarins and recovery of disease-associated 27- to 34-nm viruslike particles. Proc Natl Acad Sci USA 1987;84(17):6277–81.

[19] Li TC, Yamakawa Y, Suzuki K, et al. Expression and self-assembly of empty virus-like particles of hepatitis E virus. J Virol 1997;71(10):7207–13.

[20] Li TC, Takeda N, Miyamura T. Oral administration of hepatitis E virus-like particles induces a systemic and mucosal immune response in mice. Vaccine 2001;19(2526):3476–84.

[21] Xing L, Kato K, Li T, et al. Recombinant hepatitis E capsid protein self-assembles into a dual-domain T = 1 particle presenting native virus epitopes. Virology 1999;265(1):35–45.

[22] Ball JM, Hardy ME, Atmar RL, Conner ME, Estes MK. Oral immunization with recombinant Norwalk virus-like particles induces a systemic and mucosal immune response in mice. J Virol 1998;72(2):1345–53.

[23] Ball JM, Graham DY, Opekun AR, Gilger MA, Guerrero RA, Estes MK. Recombinant Norwalk virus-like particles given orally to volunteers: phase I study. Gastroenterology 1999;117(1):40–8.

[24] Purcell RH, Emerson SU. Animal models of hepatitis A and E. Ilar J 2001;42(2):161–77.

[25] Tsarev SA, Emerson SU, Tsareva TS, et al. Variation in course of hepatitis E in experimentally infected cynomolgus monkeys. J Infect Dis 1993;167(6):1302–6.

[26] Tsarev SA, Tsareva TS, Emerson SU, et al. Experimental hepatitis E in pregnant rhesus monkeys: failure to transmit hepatitis E virus (HEV) to offspring and evidence of naturally acquired antibodies to HEV. J Infect Dis 1995;172(1):31–7.

[27] Uchida T, Win KM, Suzuki K, et al. Serial transmission of a putative causative virus of enterically transmitted non-A. Jpn J Exp Med 1990;40:13–21.

[28] Aye TT, Uchida T, Ma X, et al. Sequence and gene structure of the hepatitis E virus isolated from Myanmar. Virus Genes 1993;7(1):95–109.

[29] Li TC, Zhang J, Shinzawa H, et al. Empty virus-like particle-based enzyme-linked immunosorbent assay for antibodies to hepatitis E virus. J Med Virol 2000;62(3):327-33.

[30] Supanaranond K, Takeda N, Yamazaki S. The complete nucleotide sequence of a variant of Coxsackievirus A24, an agent causing acute hemorrhagic conjunctivitis. Virus Genes 1992;6(2):149-58.

[31] Tsarev SA, Emerson SU, Reyes GR, et al. Characterization of a prototype strain of hepatitis E virus. Proc Natl Acad Sci USA 1992;89(2):559-63.

[32] Purdy MA, McCaustland KA, Krawczynski K, Spelbring J, Reyes GR, Bradley DW. Preliminary evidence that a trpE-HEV fusion protein protects cynomolgus macaques against challenge with wild-type hepatitis E virus (HEV). J Med Virol 1993;41(1):90-4.

[33] Tsarev SA, Tsareva TS, Emerson SU, et al. Successful passive and active immunization of cynomolgus monkeys against hepatitis E. Proc Natl Acad Sci USA 1994;91(21):10198-202.

[34] Tsarev SA, Tsareva TS, Emerson SU, et al. Recombinant vaccine against hepatitis E: dose response and protection against heterologous challenge. Vaccine 1997;15(17-18):1834-8.

[35] Bryan JP, Tsarev SA, Iqbal M, et al. Epidemic hepatitis E in Pakistan: patterns of serologic response and evidence that antibody to hepatitis E virus protects against disease. J Infect Dis 1994;170(3):517-21.

[36] Tsarev SA, Tsareva TS, Emerson SU, et al. Infectivity titration of a prototype strain of hepatitis E virus in cynomolgus monkeys. J Med Virol 1994;43(2):135-42.